Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The firm uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!